References

Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study

10.1016/j.annonc.2024.11.012 · 2025 · External reference

Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer

10.1056/nejmoa2402141 · 2024 · External reference

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

10.1016/s0140-6736(24)02848-4 · 2025 · External reference

Treatment of metastatic colorectal cancer: ASCO guideline

10.1200/jco.22.01690 · 2023 · External reference

Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting

10.1016/j.ejca.2023.113433 · 2024 · External reference

Liver metastases and peritoneal metastases and response to checkpoint inhibitors in metastatic colorectal cancer with microsatellite instability

10.1093/oncolo/oyae249 · 2024 · External reference

Clinical response to immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases

10.1001/jamanetworkopen.2021.18416 · 2021 · External reference

Liver metastases and immune checkpoint inhibitor efficacy in patients with refractory metastatic colorectal cancer: a secondary analysis of a randomized clinical trial

10.1001/jamanetworkopen.2023.46094 · 2023 · External reference

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

10.1016/j.eclinm.2023.101917 · 2023 · External reference

Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial

10.1001/jamaoncol.2022.7845 · 2023 · External reference

Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases

10.1016/j.ejca.2023.113437 · 2024 · External reference

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

10.1038/s41591-024-03083-7 · 2024 · External reference

Metastatic sites and lesion numbers cooperated to predict efficacy of PD-1 inhibitor-based combination therapy for patients with metastatic colorectal cancer

10.1002/cam4.5959 · 2023 · External reference

Effect of liver metastases on survival in microsatellite-stable metastatic colorectal cancer treated with immune checkpoint inhibitors

10.1158/2767-9764.crc-25-0690 · 2026 · External reference

Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study

10.1200/jco.23.02728 · 2024 · External reference

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study

10.1016/j.esmoop.2025.104135 · 2025 · External reference

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study

10.1200/jco.23.02736 · 2024 · External reference

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

10.1016/j.annonc.2024.03.009 · 2024 · External reference

The liver-immunity nexus and cancer immunotherapy

10.1158/1078-0432.ccr-21-1193 · 2022 · External reference

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

10.1038/s41591-020-1131-x · 2021 · External reference

IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction

10.1016/j.jhep.2023.12.015 · 2024 · External reference

Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy

10.1073/pnas.2105323118 · 2021 · External reference

Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level

10.1158/2159-8290.cd-21-0316 · 2022 · External reference

Immune phenotypic linkage between colorectal cancer and liver metastasis

10.1016/j.ccell.2022.02.013 · 2022 · External reference

Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor-associated SPP1+ macrophages and fibroblasts

10.1158/1078-0432.ccr-22-2041 · 2023 · External reference

Peritumoral immune-suppressive mechanisms impede intratumoral lymphocyte infiltration into colorectal cancer liver versus lung metastases

10.1158/2767-9764.crc-23-0212 · 2023 · External reference

The histological growth patterns in liver metastases from colorectal cancer display differences in lymphoid, myeloid, and mesenchymal cells

10.1002/mco2.70000 · 2024 · External reference

Molecular characterization of the histopathological growth patterns of colorectal cancer liver metastases by RNA sequencing of targeted samples at the tumor-liver interface

10.1007/s10585-024-10319-w · 2024 · External reference

Classifying histopathological growth patterns for resected colorectal liver metastasis with a deep learning analysis

10.1093/bjsopen/zrae127 · 2024 · External reference

Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)

10.1016/j.esmoop.2025.105508 · 2025 · External reference

Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer

10.1056/nejmoa2400634 · 2024 · External reference

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial

10.1038/s41591-024-03250-w · 2024 · External reference

Immunotherapy in localized colorectal cancer: current practice and future directions

10.1200/edbk-26-520600 · 2026 · External reference

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial

10.1016/j.esmogo.2025.100226 · 2025 · External reference

Prospective study of perioperative circulating tumor DNA dynamics in patients undergoing hepatectomy for colorectal liver metastases

10.1097/sla.0000000000005461 · 2023 · External reference

Recurrence prediction by circulating tumor DNA in the patient with colorectal liver metastases after hepatectomy: a prospective biomarker study

10.1245/s10434-023-13362-1 · 2023 · External reference

Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study

10.1097/js9.0000000000001236 · 2024 · External reference

Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up

10.1016/j.annonc.2026.03.005 · 2026 · External reference

Differential cytokine and chemokine expression after ablation vs. resection in colorectal cancer liver metastasis

10.1016/j.sopen.2024.01.005 · 2024 · External reference

Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases

10.1002/14651858.cd012757.pub2 · 2024 · External reference